Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes have?

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes has 19 citations in the OpenAlex counts ScholarIQ stores.

When was Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes published?

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes has 2025 year in the ScholarIQ index.

What is the open-access status of Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes?

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes has diamond oa status in the ScholarIQ index.

What is the DOI of Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes?

The DOI for Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes is on the source record.

What is the PMID of Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes?

The PMID for Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes is on the source record.

What is the OpenAlex record for Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes?

The OpenAlex for Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes is on the source record.